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potential parameters for nodal involvement were collected using standardized
documentation forms; surgical complications, mortality and disease-free sur-
vival were obtained by a central registry. The starting date of follow-up of
each patient began at screening colonoscopy.
Results: 180 pT1 tumors were diagnosed, 140 (77.8%) were completely
removed by endoscopy (en-bloc = 80.0%, piecemeal = 20.0%), the remaining
40 (22.2%) were biopsed and referred to surgery. Out of 140 malignant
adenomas endoscopically removed, 94 (67.1%) underwent resective surgery,
3 of them (3.2%, all with high-risk adenomas) showed nodal involvement
compared with 3/40 (7.5%) directly sent to surgeon. Out of 24 patients with
low-risk adenomas, 7 (29.2%) underwent surgery: no metastatic nodes were
found. Surgical complications were observed in 15.8% patients. Among 145
patients followed up for at least 36 months (median = 78; 10-90 percentile:
43-152), 5 (5.12*1000 PY) died for their neoplastic disease and 2 showed
disease progression; out of 142 patients with Dukes A neoplasia, 4 (4.19*1000
PY, all of them underwent surgery) died due to colon cancer and 2 showed
disease progression. Regarding histologic and therapeutic quality indicators,
the number of removed nodes during surgery was <7 in 59 patients (44.4%),
histologic description of endoscopically removed adenomas was considered
complete in 88.9% of cases, a second pathologic opinion was requested in
24.4% of patients.
Conclusions: Nodal metastatic risk in colon pT1 tumors is well predicted
by known histologic factors even in a screening scenario. However, surgi-
cal overtreatment is still significantly present and there is ample room for
improvement regarding diagnostic and therapeutic flow-chart.
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Background and aim: Lynch Syndrome (LS) is caused by constitutional
mutations in Mismatch Repair genes, but it can also be due to heritable epi-
modifications of the same genes. The genetic basis of constitutional MSH2
promoter methylation has been clarified to be caused by deletion of distal re-
gion of EPCAM, a gene located upstream the MSH2 locus. EPCAM deletions,
leaving intact the MSH2 gene, are responsible of transcriptional read-through,
with production of fusion EPCAM/MSH2 transcripts. This deletion results in
inherited allele-specific methylation of MSH2 promoter and gene silencing
with a colon-specific phenotype.
Material and methods: Out of 38 Lynch families followed at our Institu-
tion, 2 families (5.2%) displayed MSH2-negative immunoistochemistry with
EPCAM mutations. EPCAM deletion screening was performed by MLPA
(Multiplex Ligation-Dependent Probe Amplification) and long-range PCR
across the deletion was applied to identify the exact breakpoints. PCR prod-
ucts were sequenced at various positions in both orientations. Methylation
analysis was performed by SALSA MS-MLPA Mismatch Repair genes using
DNA isolated from formalin fixed paraffin embedded material.
Results: EPCAM deletions were: span 4.9kb including exons 8-9 in one
family and 16.6kb including exons 5-9 in the others. The breakpoints have
been characterized, confirming that both large deletions are caused by non-
allelic homologous recombination events between Alu elements with high
inter-homology located in intronic and intergenic regions. In one patient with
the larger deletion we showed that in colorectal tissue deletion leads to hy-
permethylation of MSH2 promoter, production of different out-of-frame and
in-frame fusion EPCAM/MSH2 transcripts and loss of nuclear expression of
MSH2 protein. Six members of the 2 EPCAM families are in follow-up. The
clinical phenotype was characterized by early colo-rectal cancer (CRC) onset
(mean 37 years, range 25–46) and multiple CRCs (up to 4 cancers despite
colonoscopy surveillance). The first CRC diagnosed in 4 patients out of 5 was
at the rectum. 1 patient developed duodenal carcinoma as extra-colonic cancer
(EXC).
Conclusions: The phenotype of LS patients, carrying EPCAM deletions, was
characterized by multiple primary cancers at colon-rectum with rectal cancer
as the first tumor diagnosed. EXCs were observed suggesting the surveillance
should not be focused only on CRC.
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Background and aim: Understanding the risk factors for Colorectal cancer
(CRC) is crucial to the development of effective strategies for its prevention.
Meta-analysis and epidemiological studies have already shown that Type 2
diabetes mellitus (DM) is associated with an increased risk of CRC and have
provided data to support a positive relationship between these diseases.
Material and methods: We retrospectively evaluated 741 consecutive cau-
casian patients with type 2 DM who underwent colonoscopic screening for
colorectal cancer and followed in our tertiary referral center in 2000-08 for the
incidence of CRC. Patients were stratified based on gender, age, body mass
index (BMI), alcohol and NSAIDS assumption, family history for cancer,
blood glycated hemoglobin levels, hypertension, hypertriglyceridemia, age at
diabetes onset and duration, treatment with insulin or other hypoglycemic
drugs. A total of 257 consecutive control patients were selected from a cohort
of patients followed as outpatients for thyroid diseases.
Results: At a median follow up of 132.5 months (range 33.3–175.7) 56 cases
of cancer (prevalence 7,56%) occurred; among these, 14 cases of CRC were
reported (prevalence 1,88%) among the diabetic patients, while only one case
(prevalence 0,004%) occurred in the control group, although this difference
is not statistically significant (chi-square 2,9, p=0,08). Median duration of
DM to CRC diagnosis was 156 months (range 1–768). At the univariate
analysis older age (p=0.001), and diabetes duration (p=0.001) were related
to higher risk of cancer, while metformin seems to be protective towards
cancer (p=0.058). In the subset of patients with CRC, older age (p=0.001)
and diabetes duration (p=0.001) were related to higher risk of CRC, such as
treatment with sulphonylureas (p=0.01).
Conclusions: Our preliminar data show that the prevalence of CRC in the
cohort of patients with type 2 DM was higher compared to that from our
control group, and to that from the National Tumor Register up 2010 (0,5%).
Furthermore we could interestingly hypotize that sulphonylureas may play a
role in CRC carcinogenesis altering the physiological insulin secretion.
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Background and aim: Esophagogastroduodenoscopy (EGD), even if it is an
invasive procedure, is an essential and very commonly used procedure for the
evaluation of a multitude of gastrointestinal (GI) symptoms. Although it is
increasingly required, the benefit of sedative premedication remains contro-
versial. The same way, the influence of the time interval between arrival at the
endoscopic suite and the effective endoscopic examination, is not clear. Our
study assesses the waiting time impact on tolerance during upper endoscopy.
Material and methods: Our study included consecutive outpatients under-
going diagnostic EGD for various indications. Sex, age, BMI, previous
endoscopic experiences, antidepressant therapy and the waiting time were
recorded. Anxiety before the procedure was rated on an ascending scale from
0 to 10 (0 = no anxious to 10 = extremely anxious). After the procedure
was concluded, patients were monitored in the recovery room. Afterwards, a
questionnaire was filled in by the participants to determine pain and discom-
fort to the procedure based on a scale from 1 to 10 (0 = no pain/discomfort
encountered to 10 = extremely painful/uncomfortable).
Results: 80 (32 males; mean age 57.2 years) consecutive outpatients were
